Cost-effectiveness of empagliflozin in heart failure patients irrespective of ejection fraction in England.

ABSTRACT:

Aims

Heart failure (HF) is a complex syndrome commonly categorized into two main phenotypes [left ventricular ejection fraction (LVEF) below or above 40%], and although empagliflozin is the first approved medication with proven clinical effectiveness for both phenotypes, its cost-effectiveness of treating the entire HF population remains unknown.

Methods

The analysis was performed utilizing two preexisting, LVEF phenotype-specific cost-effectiveness models to estimate the cost-effectiveness of empagliflozin in adults for the treatment of symptomatic chronic HF, irrespective of ejection fraction (EF). The results of the phenotype-specific models were combined using a population-weighted approach to estimate the deterministic and probabilistic incremental cost-effectiveness ra

SUBMITTER: Kolovos S 

PROVIDER: S-EPMC10481921 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature